Article content continued

That raised questions about Aphria, one of the biggest Canadian producers with U.S. investments.

“In terms of Aphria’s U.S. assets, I would like to convey the message that we have no delisting request whatsoever from any regulator,” Neufeld told analysts on a call to discuss its second-quarter earnings Wednesday. “And we remain on a path that will be receptive to the regulators, while at the same time, provide proper value to our shareholders.”

Neufeld said in December the pot producer was in dialogue with the TMX Group and it was moving to reduce, where possible, any direct involvement in medical cannabis in the U.S., including by moving assets under subsidiary companies.

Its Florida business already operates under the subsidiary Liberty Health Sciences, which it launched to acquire and operate U.S.-based companies in the medical cannabis market and the company has said it is looking to do the same for its Arizona licensed producer, Copperstate Farms.

At the same time the TMX announced its strict policy, the umbrella organization for Canada’s provincial and territorial securities regulators said that cannabis companies with U.S. operations were clear to list in Canada as long as they disclosed risks to investors. The Canadian Securities Administrators said this week it is “examining the recent recission of the Cole Memorandum.”

“Given the critical importance of the legal and regulatory environment to issuers operating in this industry, we expect issuers to carefully consider whether this development results in material changes that trigger timely disclosure obligations,” the CSA said in an emailed statement.